AIM: The aim of this study was to describe a case series of @entity1 with primary or @entity1701 ( @entity1701 ) treated with direct oral anticoagulants (DOACs). @entity1 AND METHODS: Clinical charts of eight @entity1 with @entity715 primary or secondary @entity1701 treated with direct oral anticoagulants (DOACs) between January 2012 and May 2015 were reviewed. RESULTS: The mean age was 45        14.36 (range 27-69 years). Four @entity1 had secondary @entity1701 (50%). All @entity1 were initially treated with @entity1229 by a mean time of 70.87        57.32 months (range 17-153 months). Changes in anticoagulation were defined by recurring @entity715 in five @entity1 (62.5%) and life-threatening bleeding in the other three cases. Seven @entity1 (87.5%) received @entity3925 treatment and one @entity1 (12.5%) @entity5424 . The mean follow-up period with DOACs was 19        10.06 months (range 2-36 months). There was no recurrence of @entity715 by the time of data collection. CONCLUSIONS: Despite not being the standard treatment in @entity1701 , we propose DOACs as a rational alternative for the management of @entity1 with this diagnosis. Further interventional clinical studies are necessary for possible standardization of this therapy in @entity1701 @entity1 .

Direct oral anticoagulants in XXXX : a real life case series.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity1701 :: ('MESH:D016736', 'Disease') :: ['APS', 'secondary antiphospholipid syndrome'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1701 :: (MESH:D016736,Disease) :: ['antiphospholipid syndrome']
